Isoquercitrin

DB16403InvestigationalSmall molecule

Isoquercitrin is under investigation in clinical trial NCT04622865 (Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19).

Mechanism: Pharmacologically active on Maltase-glucoamylase, Protein disulfide-isomerase, and Serine/threonine-protein kinase STK11
Curator reviewed
Formula / weight: C₂₁H₂₀O₁₂ · 464.379 g/mol (avg)
Also known as: Isoquercetin enzymatically modified · Isoquercitroside · Isotrifoliin · Isotrifolin · Quercetin 3-(beta-D-glucofuranoside)
Code names: FEMA NO. 4225

Resolves to

Compound

UNII0YX10VRV6JCAS21637-25-2ChEBI28299

Structure

InChIKeyOPJZLUXFQFQYAI-GNPVFZCLSA-NSMILES[H][C@@]1(O[C@@H](OC2=C(OC3=C(C(O)=CC(O)=C3)C2=O)C2=CC=C(O)C(O)=C2)[C@H](O)[C@H]1O)[C@H](O)CO

Targets

O43451MGAMP07237P4HBQ15831STK11

What you can answer from here — as of July 08, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Isoquercitrin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account